Drug treatment patterns in bipolar disorder: Analysis of long-term self-reported data

International Journal of Bipolar Disorders

Volumn 1, Issue 1, 2013, Pages 1-8

  Bauer, Michael ^a   Glenn, Tasha ^b   Alda, Martin ^c   Sagduyu, Kemal ^d   Marsh, Wendy ^e   Grof, Paul ^f,g   Munoz, Rodrigo ^h   Severus, Emanuel ^a   Ritter, Philipp ^a   Whybrow, Peter C ⁱ  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b ChronoRecord Association Inc   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g Mood Disorders Center of Ottawa   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bipolar disorder; Drug load; Drug treatment patterns; Polypharmacy

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; MOOD STABILIZER; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DISORDER; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; SELF MEDICATION; STRUCTURED INTERVIEW;

EID: 84924759696     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/2194-7511-1-5     Document Type: Article

References (54)

1. Azorin JM, Aubrun E, Bertsch J, Reed C, Gerard S, Lukasiewicz M. Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months - European mania in bipolar longitudinal evaluation of medication. BMC Psychiatry. 2009; 9:33.
2. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008a; 59:1175-1183.
3. Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008b; 23:95-105.
4. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007; 58:85-91.
5. Barbui C, Nosè M, Mazzi MA, Thornicroft G, Schene A, Becker T, Bindman J, Leese M, Helm H, Koeter M, Weinmann S, Tansella M. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol. 2006; 21:355-362.
6. Barr AM, Honer WG, Johnson JL, Wu TK, Procyshyn RM. A comparison of antipsychotic drug-defined daily doses versus chlorpromazine equivalent doses in patients with or without extrapyramidal motor symptoms. J Clin Psychopharmacol. 2010; 30:741-743.
7. Bauer M, Glenn T, Keil M, Bauer R, Marsh W, Grof P, Alda M, Sagduyu K, Murray G, Quiroz D, Baethge C, Whybrow PC. Brief depressive symptoms in patients with bipolar disorder: analysis of long-term self-reported data. Aust N Z J Psychiatry. 2012; 46:1068-1078.
8. Bauer M, Glenn T, Grof P, Schmid R, Pfennig A, Whybrow PC. Subsyndromal mood symptoms: a useful concept for maintenance studies of bipolar disorder? Psychopathology. 2010; 43:1-7.
9. Bauer M, Glenn T, Grof P, Marsh W, Sagduyu K, Alda M, Murray G, Lewitzka U, Schmid R, Haack S, Whybrow PC. The association between concurrentpsychotropic medications and self-reported adherence with taking a mood stabilizer in bipolar disorder. Hum Psychopharmacol. 2009; 25:47-54.
10. Bauer M, Wilson T, Neuhaus K, Sasse J, Pfennig A, Lewitzka U, Grof P, Glenn T, Rasgon N, Bschor T, Whybrow PC. Self-reporting software for bipolar disorder: validation of ChronoRecord by patients with mania. Psychiatry Res. 2008; 159:359-366.
11. Bauer M, Grof P, Gyulai L, Rasgon N, Glenn T, Whybrow PC. Using technology to improve longitudinal studies: self-reporting with ChronoRecord in bipolar disorder. Bipolar Disord. 2004; 6:67-74.
12. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J Psychopharmacol. 2009; 23:574-591.
13. Besag FM, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf. 2006; 29:95-118.
14. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand. 2006; 113:135-141.
15. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry. 2004; 161:700-706.
16. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989; 261:3273-3277.
17. Curtin F, Schulz P. Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. J Affect Disord. 2004; 78:201-208.
18. Deckers CL. Overtreatment in adults with epilepsy. Epilepsy Res. 2002; 52:43-52.
19. Deckers CL, Hekster YA, Keyser A, van Lier HJ, Meinardi H, Renier WO. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia. 2001; 42:1387-1394.
20. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005; 7:424-430.
21. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000; 61:9-15.
22. Ghaemi SN, Ko JY. Polypharmacy in bipolar disorder. In: Ghaemi SN, editor. Polypharmacy in psychiatry. New York: Marcel Dekker; 2002: p. 35-79.
23. Goldberg JF, Brooks JO 3rd, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, Miklowitz DJ, Ketter TA, Sachs GS, Thase ME. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry. 2009; 70:155-162.
24. Greil W, Häberle A, Haueis P, Grohmann R, Russmann S. Harmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord. 2012; 136:534-542.
25. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009; 10:85-116.
26. Hayes J, Prah P, Nazareth I, King M, Walters K, Petersen I, Osborn D. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS One. 2011; 6:e28725.
27. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008; 31:213-224.
28. Insel TR. Disruptive insights in psychiatry: transforming a clinical discipline. J Clin Invest. 2009; 119:700-705.
29. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005; 293:2528-2530.
30. Lammers MW, Hekster YA, Keyser A, Meinardi H, Renier WO, van Lier H. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia. 1995; 36:440-446.
31. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs. 2006; 20:29-42.
32. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002; 105:164-172.
33. Lucado J, Paez K, Elixhauser A. Medication-related adverse outcomes in U.S. hospitals and emergency departments, 2008. In: HCUP Statistical Brief #109. Agency for Healthcare Research and Quality. Rockville, MD; 2011. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb109.pdf. Accessed 25 March 2012.
34. Malhi GS, Bargh DM, McIntyre R, Gitlin M, Frye MA, Bauer M, Berk M. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord. 2012; 14(Suppl 2):1-21.
35. McIntyre RS, Konarski JZ, Soczynska JK, Wilkins K, Panjwani G, Bouffard B, Bottas A, Kennedy SH. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006; 57:1140-1144.
36. Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes. 2005; 15(3):72.
37. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010; 67:26-36.
38. Nosè M, Tansella M, Thornicroft G, Schene A, Becker T, Veronese A, Leese M, Koeter M, Angermeyer M, Barbui C. Is the defined daily dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol. 2008; 23:287-290.
39. Perlick DA, Rosenheck RA, Kaczynski R, Kozma L. Medication non-adherence in bipolar disorder: a patient-centered review of research findings. Clin Approaches Bipolar Disord. 2004; 3:56-64.
40. Post RM, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, McElroy SL, Leverich GS, Luckenbaugh DA, Rowe M, Pizzarello S, Kupka RW, Grunze H, Nolen WA. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry. 2010; 71:1176-1186.
41. Poulsen RL. Some current factors influencing the prescribing and use of psychiatric drugs. Public Health Rep. 1992; 107:47-53.
42. Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, Johnson JL, Barr AM. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry. 2010; 71:566-573.
43. Quante A, Zeugmann S, Regen F, Engelhardt A, Anghelescu IG. Psychopharmacological treatment status in outpatients with bipolar disorder: a clinical survey in Germany. Psychiatry Investig. 2010; 7:155-162.
44. Robertson TA, Cooke CE, Wang J, Shaya FT, Lee HY. Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension. Am J Manag Care. 2008; 14:710-716.
45. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics. 2005; 46:464-494.
46. Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E, Nierenberg AA, Calabrese JR, Sachs GS, Pollack MH, STEP-BD Investigators. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004; 24:512-520.
47. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. 2007; 9:394-412.
48. Tamayo JM, Zarate CA Jr, Vieta E, Vázquez G, Tohen M. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2010; 13:813-832.
49. Thistlewaite JE, Ajjawi R, Aslani P. The decision to prescribe: influences and choice. InnovAiT. 2010; 3:237-243.
50. Tognoni G. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders. Eur J Clin Pharmacol. 1999; 55:685-690.
51. Van Berge Henegouwen MT, van Driel HF, Kasteleijn-Nolst Trenite DG. A patient diary as a tool to improve medicine compliance. Pharm World Sci. 1999; 21:21-24.
52. Vincenti A, Ventriglio A, Baldessarini RJ, Talamo A, Fitzmaurice G, Centorrino F. Characteristics and clinical changes during hospitalization in bipolar and psychotic disorder patients with versus without substance-use disorders. Pharmacopsychiatry. 2010; 43:225-232.
53. WHO. WHO Collaborating Centre for Drug Statistics Methodology. 2011. http://www.whocc.no (2011). Accessed 26 March 2012.
54. Wolfsperger M, Greil W, Rössler W, Grohmann R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord. 2007; 99:9-17.